Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update

K Albracht-Schulte, NS Kalupahana… - The Journal of nutritional …, 2018 - Elsevier
Strategies to reduce obesity have become public health priorities as the prevalence of
obesity has risen in the United States and around the world. While the anti-inflammatory and …

Causes and consequences of hypertriglyceridemia

CJ Packard, J Boren, MR Taskinen - Frontiers in endocrinology, 2020 - frontiersin.org
Elevations in plasma triglyceride are the result of overproduction and impaired clearance of
triglyceride-rich lipoproteins—very low-density lipoproteins (VLDL) and chylomicrons …

Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic …

U Schwab, L Lauritzen, T Tholstrup… - Food & nutrition …, 2014 - Taylor & Francis
The effects of both the amount and quality of dietary fat have been studied intensively during
the past decades. Previously, low-fat diets were recommended without much attention to the …

Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease

E Scorletti, CD Byrne - Annual review of nutrition, 2013 - annualreviews.org
Long-chain omega-3 fatty acids belong to a family of polyunsaturated fatty acids that are
known to have important beneficial effects on metabolism and inflammation. Such effects …

[图书][B] Handbook of nutraceuticals and functional foods

REC Wildman, R Wildman, TC Wallace - 2016 - taylorfrancis.com
Scientific advances in this field have not only given us a better understanding of what is an
optimal diet, but has allowed food and nutraceutical companies to market products with …

Fish oil—how does it reduce plasma triglycerides?

GC Shearer, OV Savinova, WS Harris - … BBA)-Molecular and Cell Biology of …, 2012 - Elsevier
Long chain omega-3 fatty acids (FAs) are effective for reducing plasma triglyceride (TG)
levels. At the pharmaceutical dose, 3.4 g/day, they reduce plasma TG by about 25–50% after …

Current evidence supporting the link between dietary fatty acids and cardiovascular disease

S Hammad, S Pu, PJ Jones - Lipids, 2016 - Springer
Lack of consensus exists pertaining to the scientific evidence regarding effects of various
dietary fatty acids on cardiovascular disease (CVD) risk. The objective of this article is to …

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

JJP Kastelein, KC Maki, A Susekov, M Ezhov… - Journal of clinical …, 2014 - Elsevier
Background Omega-3 fatty acids in free fatty acid form have enhanced bioavailability, and
plasma levels are less influenced by food than for ethyl ester forms. Objective The aim was …

[HTML][HTML] Safety of supplementation of omega-3 polyunsaturated fatty acids (PUFAs): a systematic review and meta-analysis of randomized controlled trials

JPC Chang, PT Tseng, BS Zeng, CH Chang, H Su… - Advances in …, 2023 - Elsevier
Background There is no comprehensive review of the evidence to support omega-3
polyunsaturated fatty acids (PUFAs) as a relatively safe and tolerable intervention. Objective …

[HTML][HTML] Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?

AM Darwesh, W Bassiouni, DK Sosnowski… - Pharmacology & …, 2021 - Elsevier
Abstract Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), has currently led to a global pandemic with …